Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome
Mario Negri Institute for Pharmacological Research
100 participants
Mar 19, 2024
OBSERVATIONAL
Conditions
Summary
This retrospective study is aimed at evaluating the levels of circulating anti-nephrin autoantibodies in patients with INS, including those with MCD/FSGS and in patients who have experienced relapse of FSGS post-transplant, compared to those of a control group of patients with nephrotic syndrome due to primary membranous nephropathy (MN).
Eligibility
Inclusion Criteria4
- Adult (>18 years) males and females
- Patients with biopsy-proven idiopathic MCD or FSGS (cases)
- Patients with biopsy-proven idiopathic membranous nephropathy (controls)
- Patients who provided consent to store their samples in the certified CRB biobank
Exclusion Criteria2
- Reasonable possibility of a secondary cause of NS (for cases) or MN (for controls) at time of blood collections
- Active viral or bacterial infections at time of blood collections
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
"Nunc MaxiSorp" ELISA plates will be coated with recombinant extracellular domain of human nephrin. Patient serum samples will be added in appropriate dilution. Plates will be then incubated with biotin-conjugated anti human IgG antibody followed by incubation with horseradish peroxidase (HRP)-avidin conjugate. Then tetramethylbenzidine substrate will be added, and absorbance read at 450 nm.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06334692